Positive Patient Stories™

Paratek Pharmaceuticals News

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/13/16Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017 
11/02/16Paratek Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results and Provides Clinical Updates 
10/26/16Paratek Pharmaceuticals, Inc. to Host R&D Day on November 17, 2016 
10/24/16Paratek Pharmaceuticals to Report Third Quarter 2016 Financial Results and Provide Update on Clinical Progress on November 2, 2016 
10/11/16Paratek, U.S. Department of Defense Enter Research Agreement to Study Omadacycline Against Biodefense Pathogens 
10/04/16Paratek to Ring Nasdaq Closing Bell Recognizing 20th Anniversary 
09/01/16Paratek Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences 
08/15/16Paratek Initiates Phase 3 Study of Oral-only Omadacycline in ABSSSI 
08/04/16Paratek Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial and Operating Results 
07/22/16Paratek Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 4, 2016 
06/27/16Paratek Announces Closing of Common Stock Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares 
06/22/16Paratek Announces Pricing of Public Offering of 4,250,000 Shares of Common Stock 
06/20/16Paratek Announces Proposed Public Offering of Common Stock 
06/20/16Paratek Accelerates Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 1b Urinary Tract Infection Study 
06/16/16Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated 
06/13/16Paratek to Present Omadacycline Microbiologic, Pharmacokinetic and Clinical Data at ASM Microbe 2016 
06/01/16Paratek Pharmaceuticals, Inc. Announces Participation in JMP Securities Life Sciences Conference 
05/10/16Paratek Receives FDA Affirmation for Design of Proposed Omadacycline Oral-Only Skin Infection Phase 3 Study: Opportunity to Accelerate Access to Broader Oral-Only Markets 
05/02/16Paratek Pharmaceuticals, Inc. Reports First Quarter 2016 Financial and Operating Results 
05/02/16Paratek Initiates Phase 1b Study of Omadacycline in Urinary Tract Infection 
04/25/16Paratek Pharmaceuticals to Report First Quarter 2016 Financial Results on May 3, 2016 
04/11/16Paratek Presents Data from Omadacycline Clinical Development Program at ECCMID 
04/11/16Paratek Presents Pre-Clinical Data on the Effects of Omadacycline on Clostridium Difficile 
04/04/16Paratek Announces Completion of Enrollment for Omadacycline Phase 3 Skin Study 
03/29/16Paratek to Present Clinical Findings at ECCMID 2016 
03/03/16Kris Peterson to Join Paratek Board of Directors 
02/23/16Paratek Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2015 Financial and Operating Results 
02/16/16Paratek Pharmaceuticals to Report Fourth Quarter 2015 Financial Results on February 23, 2016 
02/16/16Paratek Pharmaceuticals, Inc. to Present at Two Upcoming Investor Conferences 
01/28/16Paratek Pharmaceuticals, Inc. Announces Participation in LEERINK Partners 5th Annual Global Healthcare Conference 
01/06/16Paratek Accelerates Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 3 Skin Trial 

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.